Related references
Note: Only part of the references are listed.Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Andras Heczey et al.
NATURE MEDICINE (2020)
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response
Roeland Lameris et al.
NATURE CANCER (2020)
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells
Esther Drent et al.
CLINICAL CANCER RESEARCH (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
Xin Xu et al.
CLINICAL CANCER RESEARCH (2019)
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
Antonia Rotolo et al.
CANCER CELL (2018)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy
Dominique Bollino et al.
TRANSLATIONAL RESEARCH (2017)
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
Dongfang Liu et al.
PROTEIN & CELL (2017)
Natural Killer T Cells in Cancer immunotherapy
Shiny Nair et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
Marco Ruella et al.
BIODRUGS (2017)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features
Roeland Lameris et al.
IMMUNOLOGY (2016)
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Gengwen Tian et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Regulation of the T Cell Response by CD39
Maisa C. Takenaka et al.
TRENDS IN IMMUNOLOGY (2016)
Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals
Fengqin Fang et al.
CELL REPORTS (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
The Regulatory Role of Invariant NKT Cells in Tumor Immunity
Rosanna M. McEwen-Smith et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Advantages and applications of CAR-expressing natural killer cells
Wolfgang Glienke et al.
FRONTIERS IN PHARMACOLOGY (2015)
A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances
Alena A. Chekmasova et al.
BLOOD (2015)
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Andras Heczey et al.
BLOOD (2014)
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
A. C. Chan et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter et al.
BLOOD (2013)
Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis
Jennifer E. Snyder-Cappione et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Maria Themeli et al.
NATURE BIOTECHNOLOGY (2013)
Functional significance of CD57 expression on human NK cells and relevance to disease
Carolyn M. Nielsen et al.
FRONTIERS IN IMMUNOLOGY (2013)
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
Patrick J. Brennan et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Hematopoietic stem cell engineering at a crossroads
Isabelle Riviere et al.
BLOOD (2012)
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
Hiroki Torikai et al.
BLOOD (2012)
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
Grazyna Lipowska-Bhalla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
Leonid S. Metelitsa
CLINICAL IMMUNOLOGY (2011)
Immune microenvironments in solid tumors: new targets for therapy
Stephen L. Shiao et al.
GENES & DEVELOPMENT (2011)
Immunosenescence of Human Natural Killer Cells
Inmaculada Gayoso et al.
JOURNAL OF INNATE IMMUNITY (2011)
High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice
Jin Hee Kim et al.
PLOS ONE (2011)
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset
Sandra Lopez-Verges et al.
BLOOD (2010)
Regulation of multiple myeloma survival and progression by CD1d
Emmanouil Spanoudakis et al.
BLOOD (2009)
Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR
Sachiko Okamoto et al.
CANCER RESEARCH (2009)
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: Are We Nearly There Yet?''
Gianpietro Dotti et al.
HUMAN GENE THERAPY (2009)
CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system
Jennifer L. Matsuda et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
Matthias T. Stephan et al.
NATURE MEDICINE (2007)
Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation
Asha B. Pillai et al.
JOURNAL OF IMMUNOLOGY (2007)
Increased intratumor Vα24-positive natural killer T cells:: A prognostic factor for primary colorectal carcinomas
T Tachibana et al.
CLINICAL CANCER RESEARCH (2005)
Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity
M Nieda et al.
BLOOD (2004)
Modulation of human Vα24+Vβ11+ NKT cells by age, malignancy and conventional anticancer therapies
T Crough et al.
BRITISH JOURNAL OF CANCER (2004)
Molecules and mechanisms of the graft-versus-leukaemia effect
M Bleakley et al.
NATURE REVIEWS CANCER (2004)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens
AM Dickinson et al.
NATURE MEDICINE (2002)
Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
JL Matsuda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
